Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives $143.25 Average PT from Analysts

Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) has earned a consensus rating of "Buy" from the five brokerages that are currently covering the stock, Marketbeat reports. Five analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $138.25.

A number of analysts recently issued reports on the company. Piper Sandler raised their price objective on Corcept Therapeutics from $128.00 to $131.00 and gave the stock an "overweight" rating in a research report on Thursday, April 3rd. StockNews.com upgraded shares of Corcept Therapeutics from a "hold" rating to a "buy" rating in a report on Tuesday. Truist Financial set a $135.00 target price on Corcept Therapeutics in a research report on Tuesday. HC Wainwright lowered their price target on Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating for the company in a research report on Tuesday. Finally, Canaccord Genuity Group boosted their price objective on Corcept Therapeutics from $130.00 to $142.00 and gave the company a "buy" rating in a report on Tuesday, April 1st.

Corcept Therapeutics Price Performance

Shares of NASDAQ:CORT traded down $1.15 during midday trading on Tuesday, hitting $70.23. The company had a trading volume of 953,391 shares, compared to its average volume of 1,125,684. Corcept Therapeutics has a twelve month low of $25.35 and a twelve month high of $117.33. The stock has a market cap of $7.45 billion, a price-to-earnings ratio of 55.74 and a beta of 0.22. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64. The business's 50-day simple moving average is $66.86 and its 200-day simple moving average is $60.78.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.17. The business had revenue of $157.21 million during the quarter, compared to the consensus estimate of $177.93 million. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The business's revenue was up 7.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.25 EPS. On average, research analysts predict that Corcept Therapeutics will post 1.36 earnings per share for the current year.

Insider Transactions at Corcept Therapeutics

In other news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the business's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $68.08, for a total transaction of $149,776.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Sean Maduck sold 18,303 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $60.69, for a total transaction of $1,110,809.07. Following the completion of the sale, the insider now owns 85,622 shares of the company's stock, valued at approximately $5,196,399.18. The trade was a 17.61 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 236,738 shares of company stock valued at $20,476,238. 20.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Corcept Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CORT. Kestra Investment Management LLC purchased a new stake in Corcept Therapeutics during the fourth quarter worth about $27,000. Canada Pension Plan Investment Board acquired a new position in Corcept Therapeutics during the fourth quarter worth $40,000. National Bank of Canada FI purchased a new stake in Corcept Therapeutics during the fourth quarter worth $42,000. USA Financial Formulas acquired a new stake in Corcept Therapeutics in the fourth quarter valued at $54,000. Finally, Newbridge Financial Services Group Inc. acquired a new stake in Corcept Therapeutics in the fourth quarter valued at $58,000. Institutional investors and hedge funds own 93.61% of the company's stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.